Hikal Limited has filed its mandatory quarterly certificate with stock exchanges, confirming compliance with securities dematerialisation regulations for the quarter ended March 31, 2026. The submission fulfills requirements under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Filing Details

The company submitted the certificate on April 07, 2026, to both BSE Limited and National Stock Exchange of India Limited. The filing was signed by Rajasekhar Reddy, Company Secretary and Compliance Officer of Hikal Limited.

Registrar Confirmation

MUFG Intime India Private Limited, serving as Hikal's Registrar and Share Transfer Agent, issued the confirmation certificate dated April 01, 2026. The registrar confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed within prescribed timelines.

Key Confirmations by MUFG Intime

• Securities received for dematerialisation were confirmed to depositories
• All securities comprised in certificates are listed on relevant stock exchanges
• Security certificates received were mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners
• All processes completed within prescribed regulatory timelines

Corporate Information

Hikal Limited maintains its registered office at Maker Chambers-5, Nariman Point, Mumbai, with administrative operations at CBD Belapur, Navi Mumbai. The company's securities trade on BSE under scrip code 524735 and on NSE under symbol HIKAL.

The certificate was signed by Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited, confirming the registrar's compliance with all dematerialisation procedures during the quarter.

Hikal Limited has filed a comprehensive disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015 regarding the conversion of its promoter group entity Castilia Life Sciences Private Limited into a Limited Liability Partnership structure. The company submitted the disclosure on 18th February 2026 following the Ministry of Corporate Affairs approval and Certificate of Registration dated 17th February 2026.

SEBI PIT Regulations Compliance

The disclosure was made pursuant to Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Hikal submitted Form C disclosures to both BSE Limited (Scrip Code: 524735) and National Stock Exchange of India Limited (Symbol: HIKAL) detailing the transfer of equity shares resulting from the corporate conversion.

Corporate Conversion Details

The Ministry of Corporate Affairs approved the conversion on 17th February 2026, facilitating the transfer of all assets, rights, liabilities and interests to Castilia Life Sciences LLP. The conversion resulted in 3,02,31,914 shares of Hikal Limited, representing 24.52% of the company's total voting capital, being vested in the newly formed LLP structure.

Form C Disclosure Requirements

Castilia Life Sciences LLP submitted the mandatory Form C disclosure under Regulation 7(2) read with Regulation 6(2) for continual disclosure requirements. The form detailed the acquisition of shares through corporate conversion rather than market transactions, with the designated partner Sugandha Hiremath signing the disclosure documentation.

Regulatory Documentation

The comprehensive filing includes formal communications from both Hikal Limited and Castilia Life Sciences LLP confirming the share transfer mechanism. Company Secretary Rajasekhar Reddy digitally signed the disclosure at 17:00:10 on 18th February 2026, ensuring complete regulatory compliance under the SEBI framework.

The transaction represents a strategic corporate restructuring maintaining promoter group shareholding while transitioning to an optimized Limited Liability Partnership structure approved by the Ministry of Corporate Affairs.